Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.52 |
| ▸ | RAB9A | P51151 | 9/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5526278 | 0.90 | MEN1 (0.53) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5534710 | 0.89 | KDR (0.46) | MEN1KMT2ABTKKDRAURKA | |
| SCHEMBL3434704 | 0.82 | NPC1 (0.55) | NPC1RAB9AGAANPSR1MEN1 | |
| SCHEMBL77343 | 0.79 | NPC1 (0.47) | NPC1RAB9AGAANPSR1MEN1 | |
| SCHEMBL2536426 | 0.79 | NPC1 (0.54) | NPC1RAB9AGAANPSR1MEN1 | |
| SCHEMBL3788577 | 0.78 | BTK (0.57) | NPC1RAB9AGAANPSR1MEN1 | |
| SCHEMBL3795837 | 0.74 | NPC1 (0.46) | NPC1RAB9AGAANPSR1MEN1 | |
| SCHEMBL81569 | 0.73 | KDR (0.46) | NPC1RAB9AGAANPSR1MEN1 | |
| SCHEMBL2537989 | 0.71 | NPC1 (0.50) | NPC1RAB9AGAANPSR1MEN1 | |
| SCHEMBL28106923 | 0.70 | RAB9A (0.70) | NPC1RAB9AGAANPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710038-B2 | Pyrazole kinase modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | MAP3K1, MAP3K3, MAP3K5 | NPC1 2422/4885RAB9A 2493/4885GAA 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.